{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-22-000066","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2022-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.453567+00:00","generated_at":"2026-06-24T23:23:00.203397+00:00","sec_items":["7.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PTAB denies post-grant review of two Compass Pathways patents","bullets":["Patent Trial & Appeal Board denied institution of post-grant review for US patents 10,947,257 and 10,954,259 on June 22, 2022.","Freedom to Operate had filed petitions challenging patentability on three grounds: improper subject matter, obviousness, and lack of enablement.","Decision upholds validity of key patents covering COMPASS's psilocybin-related intellectual property.","Outcome removes near-term patent invalidation risk for Compass Pathways."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-22-000066","json":"https://secwatch.observer/filing/0001816590-22-000066.json","markdown":"https://secwatch.observer/filing/0001816590-22-000066.md","text":"https://secwatch.observer/filing/0001816590-22-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659022000066/0001816590-22-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659022000066/cmps-20220622.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T23:23:00.203397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}